financetom
Business
financetom
/
Business
/
G-III Apparel's Fiscal Q4 Non-GAAP Earnings Up, Revenue Down; Fiscal Q1, 2025 Outlook Issued; Shares Down Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
G-III Apparel's Fiscal Q4 Non-GAAP Earnings Up, Revenue Down; Fiscal Q1, 2025 Outlook Issued; Shares Down Pre-Bell
Mar 14, 2024 5:26 AM

08:06 AM EDT, 03/14/2024 (MT Newswires) -- G-III Apparel Group ( GIII ) reported fiscal Q4 non-GAAP earnings Thursday of $0.76 per diluted share, up from $0.41 a year earlier.

Analysts polled by Capital IQ expected $0.68.

Net sales for the fiscal quarter ended Jan. 31 were $764.8 million, down from $854.4 million a year earlier.

Analysts surveyed by Capital IQ expected $817 million.

For fiscal Q1, the apparel retailer expects non-GAAP net income ranging from a loss of $0.10 per diluted share to breakeven on net sales of about $615 million. Analysts polled by Capital IQ expect earnings of $0.11 per share on revenue of $608.6 million.

For fiscal 2025, the company said it expects non-GAAP net income of $3.50 to $3.60 per diluted share on net sales of about $3.2 billion. Analysts surveyed by Capital IQ expect $3.88 per share on revenue of $3.22 billion.

G-III shares were down more than 5% in recent Thursday premarket activity.

Price: 28.7, Change: -1.63, Percent Change: -5.37

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Mar 10, 2025
09:12 AM EDT, 03/10/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases. The second part of the phase 1/2 clinical study also showed reductions of...
Gold Reserve makes 'stalking horse' bid for shares in Citgo's parent
Gold Reserve makes 'stalking horse' bid for shares in Citgo's parent
Mar 10, 2025
March 10 (Reuters) - Canadian miner Gold Reserve ( GDRZF ) said on Monday its Delaware subsidiary, Dalinar Energy, has submitted an offer that could be chosen as the starting bid in a court-organized auction of shares in Venezuela-owned refiner Citgo Petroleum's parent. A federal court in Delaware, which is handling the auction for Citgo parent PDV Holding, is expected...
Arthur J. Gallagher Acquires Philippines-Based Philpacific Insurance Brokers & Managers
Arthur J. Gallagher Acquires Philippines-Based Philpacific Insurance Brokers & Managers
Mar 10, 2025
09:16 AM EDT, 03/10/2025 (MT Newswires) -- Arthur J. Gallagher ( AJG ) said Monday it has acquired the remaining shares of Philippines-based Philpacific Insurance Brokers & Managers, a commercial insurance and reinsurance broker, following a minority investment in the company. Financial terms were not disclosed. ...
Concentra Acquires Assets of Physicians Health Center, OM Management
Concentra Acquires Assets of Physicians Health Center, OM Management
Mar 10, 2025
09:09 AM EDT, 03/10/2025 (MT Newswires) -- Concentra Group (CON) said Monday it has acquired the assets of Physicians Health Center and OM Management. Financial terms weren't disclosed. The occupational health services provider will offer work injury care, physical therapy, drug testing, DOT physical exams, pre-placement exams, and other employer-related health services from its new physicians health center locations in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved